AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021

Rhea-AI Summary

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will release its Q2 financial results on August 16, 2021, after market close. A conference call will be held at 4:30 p.m. ET to discuss these results and provide a business update. Investors can access the call via the company’s website. AcelRx focuses on developing therapies for acute pain management, with FDA-approved products including DSUVIA and Zalviso. The company is also advancing products in partnership with Laboratoire Aguettant.

Positive

• Management will provide an update on business developments during the conference call.
• DSUVIA and Zalviso are FDA-approved, indicating successful product development.

Negative

• None.

HAYWARD, Calif., Aug. 9, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 16, 2021. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on August 16, 2021 to discuss the financial results and provide an update on the company's business.

The webcast is accessible by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be accompanied by a slide presentation.  A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.

Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4204 for international callers.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.  AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. AcelRx has one approved product in the U.S., DSUVIA^® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO^® in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso^® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S., is being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. AcelRx has obtained the rights to file New Drug Applications (NDAs) and, subject to U.S. Food and Drug Administration (FDA) approval, commercialize in the U.S. two of Laboratoire Aguettant's innovative, EU-approved, pre-filled syringe products – ready-to-use ephedrine and phenylephrine. DZUVEO and Zalviso are both approved products in Europe.

For additional information about AcelRx, please visit www.acelrx.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-second-quarter-2021-financial-results-call-and-webcast-on-august-16-2021-301350561.html

SOURCE AcelRx Pharmaceuticals, Inc.

FAQ

When is AcelRx's Q2 2021 financial results release?

AcelRx will release its Q2 2021 financial results on August 16, 2021.

How can I access AcelRx's conference call?

You can access the conference call by visiting AcelRx's website and navigating to the Investors page.

What products does AcelRx currently have approved?

AcelRx has FDA-approved products including DSUVIA and Zalviso.

What is the focus of AcelRx Pharmaceuticals?

AcelRx focuses on developing therapies for acute pain management.

Will AcelRx provide an update on their business during the call?

Yes, AcelRx management will discuss business updates during the conference call.